Logo
Euro Gen CJC 1295 With DAC, 2mg

Euro Gen CJC 1295 With DAC, 2mg

Euro-Gen

Research chemical / peptide reagent
  • Supplied and labelled exclusively as a research Use Only peptide reagent, not as a medicinal product, medical device, cosmetic or food.
  • Not authorised by the MHRA, EMA, FDA or other medicines regulators for any therapeutic indication or clinical application.
  • Use is subject to general laboratory chemical and biological safety regulations and to institutional governance in the jurisdiction where the research is performed.
  • Researchers are responsible for ensuring compliance with applicable laws, ethical approvals, and anti Doping rules in any context where GHRH analogues may be relevant.
Synthetic GHRH analogue peptide (CJC-1295 with DAC) for in vitro research

Description

Euro-Gen CJC 1295 With DAC, 2mg is a synthetic research peptide supplied as a lyophilised powder in a sealed vial, intended strictly for in vitro testing and laboratory research. CJC-1295 with DAC (DAC:GRF) is a long-acting analogue of growth hormone–releasing hormone (GHRH), engineered with a Drug Affinity Complex (DAC) to bind covalently to albumin and markedly extend plasma half-life compared with native GHRH or short-acting analogues. The peptide is of interest in research on growth hormone (GH) axis modulation, anti-aging biology, metabolism and tissue repair, but it is not an approved medicine. The Euro-Gen product is marketed as high-purity research-grade material and clearly labelled for research use only, not for human or veterinary administration.

Bnefits

  • Provides a defined 2 mg quantity of CJC-1295 with DAC in lyophilised form for reproducible in vitro and preclinical research.
  • Long-acting GHRH analogue with DAC modification that enables covalent albumin binding and significantly prolonged half-life, making it suitable for studying sustained GH-axis stimulation in experimental models.
  • Widely referenced in preclinical and early clinical literature investigating modulation of growth hormone and IGF-1 secretion, enabling comparative and translational research.
  • Supplied as a research-grade peptide with high claimed purity (typically >99% by HPLC), appropriate for analytical, biochemical and cellular assays.
  • Lyophilised presentation enhances stability during storage and shipment before reconstitution in a controlled laboratory environment.
  • Clearly designated as research-use-only, helping laboratories separate unlicensed experimental reagents from regulated medicinal products and avoid inadvertent clinical use.

Indications

  • No authorised therapeutic indications; this product is not licensed as a medicine or medical device.
  • Intended exclusively for in vitro and preclinical laboratory research on growth hormone–releasing hormone analogues, GH/IGF-1 axis modulation, and related endocrine signalling.
  • May be used as a tool compound in cell-based assays, receptor-binding studies, pharmacokinetic modelling, and preclinical animal research (where permitted and ethically approved) to explore long-acting GHRH analogues.
  • Not for human or veterinary injection, ingestion, inhalation, topical application, or any other route of bodily administration.

Composition

  • Active research ingredient: CJC-1295 with DAC (DAC:GRF), a synthetic analogue of human growth hormone–releasing hormone (GHRH 1–29) with a C-terminal Nε-maleimidopropionyl-Lysine (Drug Affinity Complex) extension.
  • Peptide modification (IUPAC-style): Nε30-maleimidopropionyl-[D-Ala2, Gln8, Ala15, Leu27]-Sermorelin-Lys30.
  • Representative peptide sequence (one-letter code, including DAC-linked Lys): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-(Nε-maleimidopropionyl)-Lys-NH2.
  • Empirical molecular formula (CJC-1295 with DAC): approximately C165H269N47O46 (may be listed differently in some databases depending on salt/solvent form).
  • Representative PubChem CID: 56841945 (CJC-1295 / DAC:GRF).
  • CAS Registry Number (CJC-1295 with DAC, commonly cited): 446262-90-4.
  • Supplied as a lyophilised (freeze-dried) peptide powder; any trace excipients used in lyophilisation are not typically disclosed and may vary by batch.
  • No diluent, buffer, or bacteriostatic agent is supplied with the vial; these are provided separately by the laboratory as needed.

Formulation

  • Lyophilised synthetic peptide in a sterile, sealed glass vial containing a nominal 2 mg of CJC-1295 with DAC.
  • Research-grade material with high purity (typically >99% by HPLC as claimed by the supplier) suitable for in vitro and preclinical use.
  • Designed to be reconstituted by qualified laboratory personnel with an appropriate sterile diluent (e.g. bacteriostatic water, saline or buffer) according to institutional SOPs and experimental requirements.
  • Formulated and labelled solely as a research reagent and not as a pharmaceutical dosage form for human or veterinary administration.

Packaging

  • Single glass vial containing 2 mg lyophilised CJC-1295 with DAC, closed with a rubber stopper and crimped cap.
  • Vial label typically includes product name (Euro-Gen CJC 1295 With DAC, 2mg), brand, nominal peptide content, and research-use-only warning.
  • Shipped in protective secondary packaging (e.g. carton or padded mailer) by distributors such as Express Peptides or Derma Filler Ltd to minimise damage during transit.
  • Additional product details, including structural summary, storage guidance, and usage disclaimers, are provided on the supplier’s website rather than in a printed leaflet.

Usage

  • For in vitro testing and laboratory research only; handle exclusively by suitably trained and authorised laboratory personnel.
  • Do not inject, ingest, inhale, or apply to humans or animals; any form of bodily administration is explicitly prohibited and outside the stated purpose.
  • Inspect the vial for integrity before use; do not use if the vial is cracked, the seal compromised or the lyophilised cake appears grossly abnormal.
  • Reconstitute the lyophilised peptide using an appropriate sterile laboratory-grade diluent according to your institution’s SOPs and the requirements of the planned experiment (e.g. target concentration, buffer composition).
  • Use aseptic technique for all reconstitution and sampling steps to avoid contamination and ensure experimental reliability.
  • Record batch/lot number, reconstitution details (diluent, final concentration, date and time) and storage conditions in laboratory documentation for traceability.
  • Store reconstituted solutions according to internal guidelines (e.g. aliquoting and freezing) and avoid repeated freeze–thaw cycles to minimise peptide degradation.
  • Dispose of unused peptide, vials, needles, syringes and contaminated materials as laboratory chemical/biological waste in accordance with local regulations and institutional policies.

Contraindications

  • Any use involving administration to humans or animals (e.g. injection, ingestion, inhalation, or topical application) is contraindicated and outside the product’s intended research-only purpose.
  • Should not be used as a substitute for licensed growth hormone, GHRH analogues, or any approved medicinal product for endocrine or anti-aging therapies.
  • Contraindicated in laboratories that lack appropriate facilities, safety equipment, or waste-disposal capabilities for handling synthetic peptides.
  • Individuals with known hypersensitivity to peptides or specific excipients should avoid direct contact and follow occupational health recommendations.
  • Not to be used for doping, physique enhancement, or any activity designed to circumvent anti-doping regulations in sport or competition.

Adverse Effects

  • No formal adverse effect profile exists for this commercial preparation in humans or animals because it is not intended for administration.
  • Accidental exposure in the laboratory (e.g. skin or eye contact, inhalation of dust/aerosol, or incidental ingestion) may cause non-specific irritation or sensitisation; affected areas should be rinsed with water and medical attention sought if symptoms persist.
  • Unauthorised self-administration or off-label clinical use of research-grade CJC-1295 with DAC may entail significant and unpredictable risks, including contamination, incorrect dosing, endocrine disruption, and unknown long-term safety; such practices are strongly discouraged and outside the intended use.
  • Laboratory personnel should consult and comply with institutional risk assessments and safety data for peptides and follow appropriate PPE and exposure-control measures.

Storage Conditions

  • Store unopened vials in a cool, dry place protected from light and moisture; long-term storage is typically at refrigerated or frozen temperatures (e.g. 2–8 °C or ≤ −20 °C) in line with institutional peptide-handling SOPs.
  • Avoid prolonged exposure to elevated temperatures and repeated temperature cycling; do not use if there are signs of degradation or vial compromise.
  • After reconstitution, store aliquots according to laboratory protocols (often refrigerated for short-term use or frozen for extended storage) and avoid repeated freeze–thaw cycles.
  • Keep vials out of reach of unauthorised personnel and clearly segregated from medicines, foods and cosmetics.
  • Observe any expiry or best-before dates indicated by the supplier and safely dispose of expired material according to local regulations.

Duration

Not applicable. Euro-Gen CJC 1295 With DAC, 2mg is a research reagent with no authorised therapeutic use, dosing schedule or treatment duration in humans or animals; any clinical or performance-enhancement use would be outside its intended scope and contrary to supplier guidance.

Onset

Not applicable to clinical outcomes. In experimental systems, the timing and magnitude of observed effects depend on model type, concentration, exposure schedule and protocol, and cannot be extrapolated to human therapeutic use.

Browse more Research chemical / peptide reagent

Top Treatments

Top Cities in the UK